A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets Plus Lactulose for the Treatment of Overt Hepatic Encephalopathy (OHE)
Phase of Trial: Phase II
Latest Information Update: 13 Jul 2018
At a glance
- Drugs Lactulose (Primary) ; Rifaximin (Primary)
- Indications Hepatic encephalopathy
- Focus Therapeutic Use
- Sponsors Bausch Health Companies
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 16 May 2018 Status changed from not yet recruiting to recruiting.
- 08 May 2018 New trial record